OGN Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 9.99% compared to Organon & Co.'s net margin of 33.55%. Organon & Co.'s return on equity of 79.63% beat Amgen, Inc.'s return on equity of 95.55%.

Organon & Co. has a consensus price target of $9.67, signalling upside risk potential of 32.97%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -6.13%. Given that Organon & Co. has higher upside potential than Amgen, Inc., analysts believe Organon & Co. is more attractive than Amgen, Inc..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.68%. Amgen, Inc. offers a yield of 2.76% to investors and pays a quarterly dividend of $2.38 per share. Organon & Co. pays 33.59% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.

Organon & Co. quarterly revenues are $1.6B, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Organon & Co.'s net income of $160M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Organon & Co.'s price-to-earnings ratio is 3.78x while Amgen, Inc.'s PE ratio is 26.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.30x versus 5.21x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 9.99% compared to Organon & Co.'s net margin of 33.68%. Organon & Co.'s return on equity of 79.63% beat Merck & Co., Inc.'s return on equity of 39.63%.

Organon & Co. has a consensus price target of $9.67, signalling upside risk potential of 32.97%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Organon & Co. has higher upside potential than Merck & Co., Inc., analysts believe Organon & Co. is more attractive than Merck & Co., Inc..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.68%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Organon & Co. pays 33.59% of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Organon & Co.'s net income of $160M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Organon & Co.'s price-to-earnings ratio is 3.78x while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.30x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rockwell Medical, Inc. has a net margin of 9.99% compared to Organon & Co.'s net margin of -11.01%. Organon & Co.'s return on equity of 79.63% beat Rockwell Medical, Inc.'s return on equity of -17.16%.

Organon & Co. has a consensus price target of $9.67, signalling upside risk potential of 32.97%. On the other hand Rockwell Medical, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 275.41%. Given that Rockwell Medical, Inc. has higher upside potential than Organon & Co., analysts believe Rockwell Medical, Inc. is more attractive than Organon & Co..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rockwell Medical, Inc. has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.123%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.68%. Rockwell Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & Co. pays 33.59% of its earnings as a dividend. Rockwell Medical, Inc. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are larger than Rockwell Medical, Inc. quarterly revenues of $15.9M. Organon & Co.'s net income of $160M is higher than Rockwell Medical, Inc.'s net income of -$1.8M. Notably, Organon & Co.'s price-to-earnings ratio is 3.78x while Rockwell Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.30x versus 0.45x for Rockwell Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 9.99% compared to Organon & Co.'s net margin of 42.36%. Organon & Co.'s return on equity of 79.63% beat United Therapeutics Corp.'s return on equity of 19.2%.

Organon & Co. has a consensus price target of $9.67, signalling upside risk potential of 32.97%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 7.75%. Given that Organon & Co. has higher upside potential than United Therapeutics Corp., analysts believe Organon & Co. is more attractive than United Therapeutics Corp..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.68%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & Co. pays 33.59% of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are larger than United Therapeutics Corp. quarterly revenues of $799.5M. Organon & Co.'s net income of $160M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Organon & Co.'s price-to-earnings ratio is 3.78x while United Therapeutics Corp.'s PE ratio is 18.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.30x versus 7.41x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.